Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Forum Sponsorship Forum Members (as of December 31, 2016) (as of December 31, 2016) Financial support for the Forum is derived from Membership in the Forum includes a private foundations, government agencies, industry diverse range of stakeholders from multiple sponsors, and nonprofit organizations. sectors, including the federal government, the biopharmaceutical industry, academia, Private Foundation Burroughs Wellcome Fund nonprofit organizations, and patient and Other Nonprofit Organizations disease advocacy groups. American Diabetes Association American Society for Microbiology Russ Altman (Co-Chair) Association of American Medical Colleges Stanford University Critical Path Institute Steven Galson (Co-Chair) FasterCures Amgen Inc. Friends of Cancer Research New England Journal of Medicine Margaret Anderson FasterCures Government Sponsors Center for Drug Evaluation and Research (FDA) Hugh Auchincloss National Cancer Institute (NIH) National Institute of Allergy and Infectious Diseases National Center for Advancing Translational Sciences (NIH) Christopher Austin National Institute of Allergy and Infectious Diseases (NIH) National Center for Advancing Translational Sciences National Institute of Mental Health (NIH) Linda Brady National Institute of Neurological Disorders and Stroke (NIH) National Institute of Mental Health Office of Science Policy (NIH) Gail Cassell Industry Sponsors Harvard Medical School Department of Social and AbbVie Inc. Global Medicine (Visiting) Amgen Inc. AstraZeneca Andrew Dahlem Baxalta Eli Lilly & Co. Eli Lilly & Co. James Doroshow GlaxoSmithKline National Cancer Institute Johnson & Johnson Jeffrey Drazen Merck & Co., Inc. New England Journal of Medicine Pfizer Inc. Sanofi Jodie Gillon Takeda Pharmaceuticals Achillion Pharmaceuticals
Forum Sponsorship and Membership Lynn Hudson John Orloff Brian Strom Critical Path Institute Novelion Pharmaceuticals Rutgers, the State University of S. Claiborne (Clay) Johnston Robert Ratner New Jersey Dell Medical School at The American Diabetes Association John Wagner University of Texas at Austin Michael Rosenblatt Takeda Pharmaceuticals Rusty Kelley Flagship Ventures Joanne Waldstreicher Burroughs Wellcome Fund Michael Severino Johnson & Johnson Katharine Knobil AbbVie Inc. Alan Willard GlaxoSmithKline Rachel Sherman National Institute of Neurological Freda Lewis-Hall Food and Drug Administration, Disorders and Stroke Pfizer Inc. Office of the Commissioner Carrie Wolinetz Ross McKinney Ellen Sigal National Institutes of Health, Office Association of American Friends of Cancer Research of Science Policy Medical Colleges Lana Skirboll Janet Woodcock Bernard Munos Sanofi Food and Drug Administration, Center InnoThink Center for Research in for Drug Evaluation and Research Biomedical Innovation Membership Nonprofit Patient and Disease 12% Advocacy Biopharma 9% 36% 18% Academia 24% Federal
About the Forum on Drug Discovery, Development, and Translation About the National Academies of Sciences, Engineering, and Medicine The Forum on Drug Discovery, Development, and Translation of the The National Academy of Sciences was established in 1863 by an Act National Academies of Sciences, Engineering, and Medicine was created of Congress, signed by President Lincoln, as a private, nongovernmental in 2005 by the National Academiesâ Board on Health Sciences Policy to institution to advise the nation on issues related to science and technol- provide a unique platform for dialogue and collaboration among thought ogy. Members are elected by their peers for outstanding contributions to leaders and stakeholders in government, academia, industry, foundations, research. Dr. Marcia McNutt is president. and patient advocacy with an interest in improving the system of drug The National Academy of Engineering was established in 1964 under discovery, development, and translation. The Forum brings together lead- the charter of the National Academy of Sciences to bring the practices of ers from private-sector sponsors of biomedical and clinical research, federal engineering to advising the nation. Members are elected by their peers agencies sponsoring and regulating biomedical and clinical research, the for extraordinary contributions to engineering. Dr. C. D. Mote, Jr., is academic community, and patients, and in doing so serves to educate the president. policy community about issues where science and policy intersect. The National Academy of Medicine (formerly the Institute of Medicine) The Forum convenes several times each year to identify and discuss key was established in 1970 under the charter of the National Academy of problems and strategies in the discovery, development, and translation Sciences to advise the nation on medical and health issues. Members are of drugs. To supplement the perspectives and expertise of its members, elected by their peers for distinguished contributions to medicine and the Forum also holds public workshops to engage a wide range of health. Dr. Victor J. Dzau is president. experts, members of the public, and the policy community. The Forum also fosters collaborations among its members and constituencies. For The three Academies work together as the National Academies of more information about the Forum on Drug Discovery, Development, and Sciences, Engineering, and Medicine to provide independent, objec- Translation, please visit our website at http://www.nationalacademies.org/ tive analysis and advice to the nation and conduct other activities to DrugForum. solve complex problems and inform public policy decisions. The National Academies also encourage education and research, recognize outstanding Forum Staff Morgan L. Boname, M.S. contributions to knowledge, and increase public understanding in matters Anne B. Claiborne, J.D., M.P.H. Associate Program Officer of science, engineering, and medicine. Senior Program Officer and Forum Olivia C. Yost, M.S. Director Senior Program Assistant Learn more about the National Academies of Sciences, Engineering, and Rebecca A. English, M.P.H. Medicine at www.national-academies.org. Program Officer Board on Health Sciences Policy Andrew M. Pope, Ph.D. Amanda Wagner Gee, M.S. Director Program Officer
